Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Published byOlav Viken Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction."— Presentation transcript:

1 Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients with different status in germ-line HR genes (A), germ-line BRCA1/2 (B) and PD-L1 expression (C). HR, homologous recombination. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Ann Oncol, Volume 29, Issue 8, 14 June 2018, Pages 1741–1747, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 1. Kaplan–Meier plot of updated PFS (A) and OS (B) of CBCSG006 study. GP, cisplatin plus gemcitabine; GT, ... Figure 1. Kaplan–Meier plot of updated PFS (A) and OS (B) of CBCSG006 study. GP, cisplatin plus gemcitabine; GT, paclitaxel plus gemcitabine; PFS, progression-free survival; OS, overall survival. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Ann Oncol, Volume 29, Issue 8, 14 June 2018, Pages 1741–1747, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Subpopulation treatment effect pattern (STEPP) plot of 6-month PFS rate in CBCSG006 study. (A) Distribution ... Figure 3. Subpopulation treatment effect pattern (STEPP) plot of 6-month PFS rate in CBCSG006 study. (A) Distribution of composite risk scores of CBCSG006 cohort. The vertical dashed lines indicated four quartiles of distribution. (B) 6-month PFS rates according to four-quartile composite risk subpopulations. The vertical dashed lines indicated each median composite risk of four quartiles. The rug plot along the x-axis illustrated the distribution of each composite risk value. (C) STEPP plot of 6-month PFS rate in GT and GP arms of CBCSG006 cohort according to composite risk subpopulations. (D) STEPP plot of 18-month OS rate in GT and GP arms of CBCSG006 cohort according to composite risk subpopulations. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Ann Oncol, Volume 29, Issue 8, 14 June 2018, Pages 1741–1747, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction."

Similar presentations

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.
RCTs: randomized controlled ...

RCTs: randomized controlled ...

Similar presentations

Ads by Google